At a median follow-up of 2 years, median PFS was superior with combination ipilimumab–nivolumab compared with ipilimumab monotherapy for both BRAF wild-type and mutant tumours (not reached vs. 4.4 months, HR 0.40, and 8.5 vs. 2.7 months, HR 0.38, respectively) (20). The gene discussed is BRAF; the disease is neoplasm.